尖峰集团(600668.SH)：恩格列净获得化学原料药上市申请批准

Core Viewpoint - The announcement indicates that Jianfeng Group's subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Canagliflozin, which is a SGLT2 inhibitor used for improving blood sugar control in adults with type II diabetes [1]. Group 1 - Jianfeng Pharmaceutical has received the approval notice for Canagliflozin, with the notification number 2025YS00624 [1]. - Canagliflozin functions by blocking glucose reabsorption in the kidneys, leading to reduced blood sugar levels, and its efficacy is independent of β-cell function and insulin resistance [1]. - As of the date of the announcement, there are 28 companies listed with an "A" status on the CDE raw and auxiliary package registration information platform, including Jiangsu Hengrui Medicine Co., Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. [1].